Skip to content

Uveitis Gene-Expression Profiling

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00874471
Enrollment
280
Registered
2009-04-02
Start date
2005-06-30
Completion date
Unknown
Last updated
2014-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uveitis

Brief summary

Uveitis is a group of troublesome diseases that collectively represent a cause of blindness comparable to diabetes. Most forms of uveitis are either infectious or immune-mediated. The investigators propose to create a data base on peripheral blood gene expression for patients with 3 of the most important diseases associated with uveitis: ankylosing spondylitis, sarcoidosis, and Behcet's disease. The investigators will quantitatively measure the expression of consistent alteration in peripheral blood from patients with more than 40,000 gene sequences using microarray gene chip technology. This approach is known to detect systemic immune-mediated disease. The investigators will use this data base to: 1. Determine if patients with uveitis and ankylosing spondylitis, sarcoidosis, or Behcet's can be distinguished from a normal population or controls with the same systemic disease but no history of uveitis 2. Determine if the profile of gene expression can distinguish infectious or idiopathic forms of uveitis from patients with spondylitis, sarcoidosis, or Behcet's 3. Determine how this gene profile changes over time as episodic disease such as spondylitis or Behcet's activates or remits 4. Correlate the changes in gene expression with the prognosis of the ocular inflammatory process. The creation of a gene expression data base for patients with uveitis has the potential to clarify the pathogenesis of disease, establish new diagnostic tools, and provide a means for predicting prognosis.

Interventions

None listed

Sponsors

Oregon Health and Science University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* The study group will include patients aged 21 years or older attending the Uveitis Clinic at the Casey Eye Institute at OHSU who have uveitis of the following subtypes: 1. ankylosing spondylitis 2. sarcoidosis 3. Behçet's disease 4. toxoplasmosis 5. herpetic acute retinal necrosis; AND 6. idiopathic uveitis * Another group of patients, also aged 21 years or more, with the following diseases but no uveitis, will be recruited from the Rheumatology Clinic at OHSU as follows: 1. ankylosing spondylitis 2. sarcoidosis; AND 3. Behçet's disease * The study group will also include 30 normal control volunteers aged 21 years or older.

Exclusion criteria

* Special/vulnerable subject populations (e.g., mentally impaired persons and children) will not be enrolled.

Design outcomes

Primary

MeasureTime frame
Correlation of blood transcriptome with form of uveitistime of office visit for disease evaluation

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026